Death during study period · adults with antisocial personality disorder
It is very uncertain whether psychosocial risk management ('Resettle' programme) changes adverse events: death during the study period Timing of assessment:… compared with treatment‐as‐usual (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events Measured by: proportion of serious adverse events (total) Average study duration (range): not stated · children and adolescents aged 18 years and under diagnosed with ADHD
It is very uncertain whether the intervention changes serious adverse events Measured by: proportion of serious adverse… (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events Measured by: proportion of any serious adverse events Average study duration (range): 4.7 months (14 days to 21 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Non‐serious adverse events Measured by: proportion of any non‐serious adverse events Average study duration (range): 5.99 months (1 day to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to non‐serious adverse events Measured by: proportion of participants withdrawn from treatment Average study duration (range): 5.60 months (0.6 months to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to adverse events of unknown severity Measured by: proportion of participants withdrawn from treatment Average study duration (range): 4.6 months (21 days to 36 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to serious adverse events (non‐comparative cohort studies) Measured by: proportion of participants withdrawn from treatment Average study duration (range): 7.9 months (1 month to 37 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Adverse events · children (aged 0–6 years)
The review found no eligible studies for this question.
2 findings from 1 review
Adverse events · children (aged 0–4 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children (aged 0–2 years)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · healthcare workers
1 finding from 1 review
Adverse events · healthcare students, including students in training for health professions delivering direct medical care (e.g. medical students, nursing…
1 finding from 1 review
Adverse events · children up to 5 years of age with a communication difficulty associated with any non‐progressive motor disorder acquired before 2 years…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: parental stress · parent‐child dyads (including foster or adoptive carers), where the child was aged between birth and four years 11 months (inclusive), and…
1 finding from 1 review
Adverse events: parental anxiety · parent‐child dyads (including foster or adoptive carers), where the child was aged between birth and four years 11 months (inclusive), and…
1 finding from 1 review
Adverse events None of the included studies evaluated adverse events · young people (aged 10 to 18 years old) with harmful sexual behaviour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events None of the included studies evaluated adverse events · young people (aged 10 to 18 years old) with harmful sexual behaviour
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events (not measured) · children with cerebral palsy classified within GMFCS Levels I to IV and between 4 and 18 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (not measured) · children with cerebral palsy classified within GMFCS Levels I to III and between 3 and 12 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found